Literature DB >> 3703495

The use of intravitreal thrombin to control hemorrhage during vitrectomy.

J T Thompson, B M Glaser, R G Michels, S de Bustros.   

Abstract

The ability of intravitreal bovine thrombin to control intraoperative bleeding was investigated by a prospective double blind study of 28 consecutive patients with vascularized preretinal membranes undergoing vitrectomy for diabetic retinopathy. Addition of thrombin (100 units/ml) to the vitrectomy infusate was associated with a significantly reduced intraocular bleeding time after cutting vascularized membranes. The mean bleeding time without thrombin was 111.5 seconds, compared to 12.3 seconds with intravitreal thrombin (P less than 0.0001). Patients receiving thrombin had less overall bleeding during surgery and less vitreous hemorrhage on the second postoperative day. Intravitreal bovine thrombin was associated with increased postoperative intraocular inflammation in 20% of patients receiving thrombin. This inflammation could be controlled by use of frequent topical steroids.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3703495     DOI: 10.1016/s0161-6420(86)33743-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.

Authors:  G Ratnarajan; F Mellington; M Saldanha; S R de Silva; L Benjamin
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

2.  Thrombin stimulates the proliferation of human retinal glial cells.

Authors:  D G Puro; T Mano; C C Chan; M Fukuda; H Shimada
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial.

Authors:  A R Ramezani; H Ahmadieh; A K Ghaseminejad; S Yazdani; B Golestan
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.